

## Comment on Association between Coronary Heart Disease, Heart Failure and Risk of Alzheimer's Disease

The authors<sup>[1]</sup> have attempted to evaluate the association between cardiovascular diseases (CVD) and the risk of Alzheimer's disease (AD). They came up with the results that coronary heart disease (CHD) and heart failure (HF) were associated with 22% and 53% elevated risk of AD, respectively. We believe this is a valuable topic to explore, but the results should be further analyzed to reach a stable conclusion.

AD is the leading cause of dementia. The prevalence of dementia will triple worldwide by 2050 and that estimate will be three times higher when based on a biological (rather than clinical) definition of AD.<sup>[2]</sup> CVD and AD are both common in aging populations. *Dementia in Europe Yearbook 2019* has suggested that the strong push on public health messaging on cardiovascular health and smoking cessation might be vital for reducing the prevalence of dementia.<sup>[3]</sup> In addition, cardiovascular risk factors were suggested to be associated with an increased risk of dementia.<sup>[2]</sup> The currently available treatments for AD are mainly treatments of symptoms but not curative therapies; hence, the prevention or reducing AD risk aroused great attention.<sup>[4]</sup> Identifying and managing risk factors is vital for AD prevention strategies. Previous studies suggested that early identification and correct medical treatment of cardiovascular conditions may reduce the prevalence of AD.<sup>[5]</sup> However, the relationship between CVD and AD remains unclear. The exploration of the association between CVD and AD in this study is of great clinical significance.

This study concluded that CHD and HF are associated with an increased risk of developing AD. However, the high heterogeneity ( $I^2 = 96.8\% \sim 97.2\%$ ) of this study indicates that the conclusion is unstable. The authors also mentioned the result of the association between HF and AD inconsistent with a previous research,<sup>[6]</sup> which has lower but still high heterogeneity ( $I^2 = 74.8\%$ ). The reasons for this inconsistency have not been fully explored in the article. One possible reason could be the difference in the population, as this study included patients with AD, while the previous study included patients with all-cause dementia. In addition, the improper meta-regression and subgroup analysis lead to unclear sources of heterogeneity. Only publication year, age, gender, follow-up time, population, and type of studies are considered as the heterogeneity factors. The results of meta-regression and subgroup analysis indicated none of the above factors were responsible for the heterogeneity between included studies. However, the diagnosis of AD, education level, smoking, hypertension, and body mass index, which are the factors closely related to AD<sup>[7]</sup> and CVD,<sup>[8,9]</sup> has not been analyzed as possible heterogeneity source. Further meta-regression and subgroup analysis should be conducted to reduce the heterogeneity, thereby reaching stable conclusions.

In addition, the summary and discussion of the included studies investigating the association between CVD and the risk of AD are insufficient. We noticed that most included cohort and case-control studies have mostly adjusted the currently known risk factors for AD, such as education, APOE4 status, age, gender, hypertension, body mass index, and diabetes. However, more attention should be paid to modifiable risk factors in clinical research, especially lifestyle-related factors. Previous studies have suggested that intervention of lifestyle-related factors, including physical exercise, mentally stimulating activities, social activities, smoking, diet, and alcohol use, to individuals at risk of dementia could effectively prevent cognitive impairment.<sup>[10]</sup> Particularly, cigarette smoking status, a modifiable risk factor for both CHD<sup>[9]</sup> and AD,<sup>[4]</sup> should be paid more attention to in future relevant cohort and case-control studies. The improvement of relevant clinical studies quality is vital for clarifying the relationship between CVD and AD.

**Wei Liu<sup>1,2</sup>, Wenyi Ge<sup>1,2</sup>, Xiaonong Fan<sup>1,2,3,4,5</sup>, Yuzheng Du<sup>1,2</sup>, Yibing Li<sup>1,2</sup>, Hongbo Jia<sup>1,2</sup>, Kangchen Lei<sup>1,2</sup>, Songjiao Li<sup>1,2</sup>**

<sup>1</sup>Department of Acupuncture, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, <sup>2</sup>Department of Acupuncture, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, <sup>3</sup>Department of Acupuncture, Tianjin Key Laboratory of Acupuncture and Moxibustion, Tianjin, <sup>4</sup>Department of Acupuncture, Laboratory of Dosage-Effect Relationship, National Administration of Traditional Chinese Medicine (Level 3), Tianjin, <sup>5</sup>Department of Acupuncture, Key Laboratory of Cerebrovascular Acupuncture Therapy of State Administration of Traditional Chinese Medicine, Tianjin, China

**Address for correspondence:** Dr. Xiaonong Fan, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Changling Road No. 88, Xiqing District - 300 183, Tianjin, China. E-mail: fanxiaonong@163.com

### REFERENCES

1. Sun W, Zhuo S, Wu H, Cai X. Association between coronary heart disease, heart failure and risk of Alzheimer's disease: A systematic review and meta-analysis. *Ann Indian Acad Neurol* 2023;26:958-65.
2. Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, *et al.* Alzheimer's disease. *Lancet* (London, England) 2021;397:1577-90.
3. Europe A. *Dementia in Europe Yearbook 2019: Estimating the prevalence of dementia in Europe*. 2020. Available from: [https://www.alzheimer-europe.org/sites/default/files/alzheimer\\_europe\\_dementia\\_in\\_europe\\_yearbook\\_2019.pdf](https://www.alzheimer-europe.org/sites/default/files/alzheimer_europe_dementia_in_europe_yearbook_2019.pdf). [Last accessed on 2021 Jan 24].
4. Passeri E, Elkhoury K, Morsink M, Broersen K, Linder M, Tamayol A, *et al.* Alzheimer's disease: Treatment strategies and their limitations. *Int J Mol Sci* 2022;23:13954. doi: 10.3390/ijms232213954.
5. Cermakova P, Eriksson M, Lund LH, Winblad B, Religa P, Religa D. Heart failure and Alzheimer's disease. *J Intern Med* 2015;277:406-25.
6. Li J, Wu Y, Zhang D, Nie J. Associations between heart failure and risk of dementia: A PRISMA-compliant meta-analysis. *Medicine* 2020;99:e18492.
7. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, *et al.* Dementia prevention, intervention, and care: 2020 report of the

- Lancet Commission. Lancet (London, England) 2020;396:413-46.
8. Alpert JS. New coronary heart disease risk factors. Am J Med 2023;136:331-2.
  9. Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: A systematic review and meta-analysis of prospective cohort studies. Lancet (London, England) 2011;378:1297-305.
  10. Kivipelto M, Mangialasche F, Ngandu T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat Rev Neurol 2018;14:653-66.

**Submitted:** 14-Jul-2023 **Revised:** 16-Jul-2023 **Accepted:** 18-Jul-2023

**Published:** 13-Oct-2023

---

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

**DOI:** 10.4103/aian.aian\_623\_23